Company Description
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States.
Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.
The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching.
The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021.
Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 2008 |
| IPO Date | Jun 25, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 59 |
| CEO | Ms. Jill C. Milne Ph.D. |
Contact Details
Address: 22 Boston Wharf Road, 10th Floor Boston, Massachusetts 02210 United States | |
| Phone | 617-349-1971 |
| Website | astriatx.com |
Stock Details
| Ticker Symbol | ATXS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001454789 |
| CUSIP Number | 04635X102 |
| ISIN Number | US04635X1028 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jill C. Milne Ph.D. | Co-Founder, Chief Executive Officer, President and Director |
| Benjamin S. Harshbarger J.D. | Chief Legal Officer |
| Noah C. Clauser CPA | Chief Financial Officer and Treasurer |
| Keri McGrail | Senior Vice President of Human Resources |
| Andrea L. Matthews | Chief Business Officer |
| Andrew A. Komjathy | Chief Commercial Officer |
| Dr. Christopher J. Morabito M.D. | Chief Medical Officer |
| John Ruesch | Senior Vice President of Pharmaceutical Sciences and Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 10, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jun 6, 2024 | 8-K | Current Report |
| May 9, 2024 | 10-Q | Quarterly Report |
| Apr 22, 2024 | ARS | Filing |
| Apr 22, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 22, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 9, 2024 | 8-K | Current Report |
| Apr 1, 2024 | 144 | Filing |
| Mar 25, 2024 | 8-K | Current Report |
| Mar 11, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |